Arch Biopartners Inc. (V:ARCH)

Business Focus: Biotechnology & Medical Research (NEC)

Get the company report for the most recent outlook updated daily

Apr 16, 2024 07:14 am ET

St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the...

Apr 03, 2024 07:00 am ET

UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Anesthesia Clinical Trials Unit (ACTU), an academic research organization in the Department of Anesthesia and Pain Management at the...

Apr 02, 2024 07:26 am ET

Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac...

Mar 18, 2024 07:28 am ET

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has published a peer reviewed paper in the British Medical Journal Open (BMJ Open) detailing the results of the international Phase II...

Mar 15, 2024 07:05 am ET

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from the University of Calgary’s Cumming School of Medicine has joined the Phase II trial for LSALT peptide targeting the...

Mar 07, 2024 07:26 am ET

Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing has begun in Turkey for the Phase II trial for LSALT peptide targeting the prevention and treatment of...

Feb 27, 2024 07:25 am ET

Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it had a pre-investigational new drug application (PIND) meeting with the U.S. Food and Drug Administration (FDA) Division of Cardiovascular...

Jan 10, 2024 07:26 am ET

Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received a No Objection Letter from Health Canada to conduct a Phase II trial for LSALT peptide, targeting the prevention and...

Jan 03, 2024 07:33 am ET

Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention...

Dec 21, 2023 07:30 am ET

Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval in Turkey from the Kocaeli University Clinical Research Ethics Committee to proceed with a Phase II trial for LSALT...

Dec 18, 2023 08:25 am ET

Grant of Options to Directors and Officers

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that its Board of Directors has granted a total of 350,000 stock options to directors and officers pursuant to the Company's stock option plan...

Dec 13, 2023 07:25 am ET

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has submitted a Clinical Trial Application to Health Canada to obtain permission to proceed with a Phase II trial for LSALT peptide, targeting...

Oct 24, 2023 07:30 am ET

Shares for Interest Debt Settlement

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $172,500 in interest accrued up to September 30, 2023 on all...

Sep 22, 2023 07:00 am ET

Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that it has submitted applications to the Ministry of Health (MoH) and local Ethics Committee in Turkey to obtain permission to proceed with a Phase II...

Jul 31, 2023 06:02 pm ET

Arch Biopartners Engages Independent Trading Group as Market Maker

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has engaged the services of Independent Trading Group (“ITG”) to provide market-making services in accordance with TSX Venture Exchange...

Jun 27, 2023 07:15 am ET

Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) for a Phase II human trial for LSALT peptide...

Apr 18, 2023 07:10 am ET

Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide

Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that it has safely increased the maximum...

Mar 23, 2023 07:00 am ET

Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program

Feb 07, 2023 07:05 am ET

Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease

Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, announced that an Arch...

Dec 15, 2022 09:49 am ET

Shares for Interest Debt Settlement; Grants Options

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $201,459 in interest accrued up to September 30, 2022 on...

Oct 05, 2022 07:20 am ET

Arch Biopartners Adds Farris Smith as a Strategic Advisor

Aug 05, 2022 07:30 am ET

Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with novel therapeutics, announced today that the Company has added Dr. David Luke as a Strategic...

Feb 14, 2022 07:30 am ET

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that Health Canada...

Feb 08, 2022 07:44 pm ET

Shares for Interest Debt Settlement

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $424,767.07 in interest accrued up to December 31, 2021 on...

Feb 03, 2022 07:30 am ET

Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Daniel Muruve at the University of Calgary, and their collaborators, have published a paper in the journal...

Jan 04, 2022 07:25 am ET

Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)

Dec 01, 2021 07:35 am ET

Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial

Oct 15, 2021 10:42 am ET

Unaware of Any Undisclosed Material Change

At the request of the Investment Industry Regulatory Organization of Canada (IIROC), Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) wishes to confirm that the Company’s management is unaware of any undisclosed...

Aug 05, 2021 06:30 am ET

Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today provided an update that the analysis of the...

Jul 14, 2021 07:00 am ET

Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that Arch scientists have been awarded a...

Jun 10, 2021 07:20 am ET

Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today it has filed a new provisional patent...

May 04, 2021 07:00 am ET

Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

Apr 15, 2021 07:00 am ET

Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has entered into an exclusive worldwide license agreement with Telara Pharma of Spain (“Telara”) to clinically develop and market cilastatin, a...

Mar 30, 2021 07:57 am ET

Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSALT Peptide

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval from the Turkish Ministry of Health, Pharmaceuticals and Medical Devices Agency (MoH) to recruit up to twenty additional...

Mar 24, 2021 08:25 am ET

Arch Biopartners Enters Exclusive License Agreement with the University of Cincinnati for AB569 Topical Wound Treatment

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has entered into an exclusive agreement with the University of Cincinnati (UC) to license new patent claims for an AB569 topical wound...

Mar 16, 2021 08:32 am ET

Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for preventing organ inflammation, announced today that Health Canada has provided a No Objection Letter...

Mar 04, 2021 08:32 am ET

ARCH Scientist Publishes Paper Showing Pre-Clinical Efficacy of AB569 in Eradicating Multi-Drug Resistant Pathogens Acinetobacter baumannii and Acinetobacter spp

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that one of its lead scientists, Dr. Daniel Hassett, Professor at the University of Cincinnati College of Medicine, published a paper entitled...

Feb 26, 2021 08:42 am ET

Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Peter Lougheed Center (PLC) in Calgary, Alberta has joined the Phase II trial of its lead drug LSALT peptide (Metablok), targeting the...

Feb 02, 2021 07:55 am ET

Arch Biopartners Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase II Trial for LSALT Peptide

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval in Turkey from the İstanbul University-Cerrahpaşa, School of Medicine, Clinical Research Ethics Committee to dose twenty...

Jan 05, 2021 07:50 am ET

University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary Cumming School of Medicine has joined the Phase II trial of its lead drug LSALT peptide (Metablok), targeting the...

Dec 29, 2020 08:33 am ET

Arch Biopartners Closes Non-Brokered Private Placement

Dec 23, 2020 08:53 am ET

Arch Biopartners Arranges Non-Brokered Private Placement

Dec 15, 2020 12:51 pm ET

Arch Biopartners Receives Government of Canada Funding to Support Phase II Therapeutic Trial of Metablok for COVID-19

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that the Government of Canada has...

Dec 15, 2020 12:05 pm ET

IIROC Trading Resumption - ARCH

VANCOUVER, BC, Dec. 15, 2020 /CNW/ - Trading resumes in:

Dec 15, 2020 10:35 am ET

IIROC Trading Halt - ARCH

VANCOUVER, BC, Dec. 15, 2020 /CNW/ - The following issues have been halted by IIROC:

Dec 10, 2020 07:27 am ET

VA San Diego Healthcare System Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Veterans Affairs San Diego Healthcare System (VASDHS) has started recruiting patients for the Phase II trial of its lead drug LSALT...

Nov 05, 2020 08:03 am ET

Arch Biopartners Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient dosing in Turkey has begun in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute...

Oct 16, 2020 07:00 am ET

First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has dosed the first patient in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute kidney...

Oct 07, 2020 07:57 am ET

Arch Biopartners Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide; Begins Screening Patients in Florida

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval in Turkey from the Ministry of Health to proceed with the Phase II trial of its lead drug LSALT peptide (Metablok),...

Sep 10, 2020 08:59 am ET

Arch Biopartners Receives Ethics Committee Approval in Turkey for Phase II Trial for LSALT Peptide

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval in Turkey from the Istanbul University Ethics Committee for the Phase II trial of its lead drug LSALT peptide...

Sep 01, 2020 08:00 am ET

Arch Biopartners Announces Application to the Turkish Ministry of Health to Conduct Phase II Trial for Treatment of Complications in COVID-19 patients

Aug 21, 2020 08:00 am ET

Arch Biopartners Obtains DTC Eligibility for its Common Shares on OTCQB

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced it has obtained eligibility with The Depository Trust Company (DTC) in the United States, increasing access for U.S. investors for its common shares...

Aug 18, 2020 08:16 am ET

Arch Biopartners to Hold LSALT Peptide Webinar Today at 11am EST

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) will host a webinar today at 11:00am EST to present an overview of the LSALT Peptide development program and upcoming Phase II human trial to treat inflammation in...

Aug 07, 2020 11:34 am ET

Arch Biopartners to Hold LSALT Peptide Webinar and Q&A Session August 18, 2020 at 11am EST

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it will host a webinar on August 18, 2020 at 11:00am EST to present an overview of the LSALT Peptide development program and upcoming Phase II...

Aug 04, 2020 08:00 am ET

Arch Biopartners Receives Independent Institutional Review Board Approval for Phase II Trial for LSALT Peptide

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received independent Institutional Review Board (IRB) approval for the Phase II trial of its lead drug LSALT peptide (Metablok) targeting...

Jul 28, 2020 08:13 am ET

Broward Health Medical Center Becomes First Clinical Site in U.S. for Phase II Trial for LSALT Peptide

Jul 14, 2020 07:00 am ET

Arch Biopartners Engages Global CRO to Conduct LSALT peptide (Metablok) Phase II trial for Treatment of Complications in COVID-19 Patients in the U.S.

Jun 30, 2020 09:21 am ET

Arch Biopartners Closes Non-Brokered Private Placement

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today it has closed the non-brokered private...

Jun 24, 2020 08:41 am ET

Arch Biopartners Arranges Non-Brokered Private Placement

Jun 16, 2020 11:02 am ET

IIROC Trading Resumption - ARCH

VANCOUVER, BC, June 16, 2020 /CNW/ - Trading resumes in:

Jun 16, 2020 10:48 am ET

FDA Grants Arch Biopartners Permission to Proceed with Phase II trial to Evaluate Metablok (LSALT peptide) for the Treatment of COVID-19 patients

Jun 16, 2020 08:50 am ET

IIROC Trading Halt - ARCH

VANCOUVER, BC, June 16, 2020 /CNW/ - The following issues have been halted by IIROC:

Jun 15, 2020 08:19 am ET

Arch Biopartners Announces FDA Acknowledgement of its Investigational New Drug Application for Metablok (LSALT peptide)

Jun 11, 2020 08:31 am ET

Grant of Options

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that its Board of Directors has granted a total of 1,430,000 stock options to directors, officers and certain consultants pursuant to the Company's...

Jun 08, 2020 07:00 am ET

Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide)

May 19, 2020 04:31 pm ET

Arch Biopartners Expands the Primary Endpoint of its Phase II Trial to Include Prevention of Multiple Organ Injuries in Patients with COVID-19

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has expanded the primary endpoint of...

May 08, 2020 06:00 am ET

Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial

Apr 23, 2020 04:54 pm ET

Arch Biopartners Submits Application to Health Canada to Conduct COVID19 Phase II Human Trial for Metablok to Prevent Lung and Kidney Inflammation

Mar 31, 2020 07:36 am ET

Arch Biopartners Releases New Video Showing Metablok Reducing Lung Inflammation in an Animal Model

Mar 24, 2020 07:27 am ET

ARCH BIOPARTNERS DISCLOSES NEW PATENT FILING FOR NOVEL DRUG CANDIDATES TO PREVENT LUNG INFLAMMATION

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today it has filed a new provisional patent...

Mar 17, 2020 11:49 am ET

IIROC Trading Resumption - ARCH

VANCOUVER, March 17, 2020 /CNW/ - Trading resumes in:

Mar 17, 2020 11:21 am ET

ARCH BIOPARTNERS SAFELY COMPLETES EXPANDED DOSING OF METABLOK IN PHASE I HUMAN TRIAL AND BEGINS FOCUS ON PHASE II TRIAL

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it has safely completed dosing of the final eight healthy volunteers in its Phase I human trial of Metablok (LSALT peptide). This final group...

Mar 16, 2020 09:42 am ET

IIROC Trading Halt - ARCH

VANCOUVER, March 16, 2020 /CNW/ - The following issues have been halted by IIROC:

Mar 04, 2020 09:56 am ET

Arch Biopartners Expands Dosing in Phase I Trial for Metablok to Increase Dose Range for Future Phase II Studies

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it is expanding the dose range of Metablok (LSALT peptide) for future Phase II trials targeting inflammation in the lung, the kidney and/or...

Feb 21, 2020 08:00 am ET

Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Dr. Daniel Hassett’s team at the University of Cincinnati (UC) College of Medicine, and its collaborators, have published details regarding...

Feb 06, 2020 08:31 am ET

Arch Biopartners Closes Convertible Note Financing

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has closed the non-brokered, unsecured convertible note (“Note”) financing it disclosed in a press release on February 4th for net proceeds of CAD...

Feb 04, 2020 08:36 am ET

Arch Biopartners Arranges Convertible Note Financing

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has arranged a non-brokered, unsecured convertible note (“Note”) financing for gross proceeds of CAD $500,000 (the “Offering”). The Note matures...

Dec 18, 2019 09:27 am ET

Arch Biopartners Announces Metablok Achieves Primary Endpoints of Safety and Tolerability in Phase I Trial

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Phase I human trial of Metablok (LSALT peptide) has completed dosing of all scheduled volunteers and Metablok has met the primary...

Dec 04, 2019 08:46 am ET

Arch Biopartners Announces Issuance of U.S. Patent for Dipeptidase-1 Inhibitor Drug for Use in Acute Kidney Injury

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today the U.S. Patent and Trademark Office...

Nov 07, 2019 07:00 am ET

Arch Provides Interim Update on Phase I Trial for Metablok (LSALT Peptide)

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Phase I human trial of Metablok (LSALT peptide), the Company’s lead drug candidate for treating organ damage caused by inflammation, has...

Aug 22, 2019 12:24 pm ET

Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate Metablok in the Prevention of Inflammation and Organ Damage

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Donna Senger, Dr. Stephen Robbins and Dr. Paul Kubes at the University of Calgary, and their collaborators, have...

Jun 19, 2019 07:20 am ET

Arch Biopartners Announces Start of Phase I Human Trial for Metablok

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has initiated the Phase I human trial for Metablok (“LSALT peptide”), the Company’s lead drug candidate for treating acute kidney injury and...

May 22, 2019 05:01 pm ET

Arch Biopartners Closes Convertible Note Financing

May 17, 2019 07:00 am ET

Arch Biopartners Arranges Convertible Note Financing

Mar 19, 2019 08:46 am ET

Arch Biopartners Receives Approval to Perform Phase I Clincial Trial for Metablok in Australia

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that it has been granted approval by the Alfred Hospital Ethics Committee to perform a Phase I clinical trial for Metablok, the Company’s lead...

Feb 07, 2019 08:00 am ET

Arch Biopartners Awarded NRC-IRAP Funding to Further Develop Metablok Drug Program

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that the National Research Council – Industrial Research Assistance Program (“NRC-IRAP”) has approved funding totaling $200,000 for Arch...

Jan 29, 2019 08:46 am ET

Arch Biopartners Closes Convertible Note Financing

Jan 24, 2019 08:43 am ET

Arch Biopartners Arranges Convertible Note Financing

Dec 11, 2018 08:02 am ET

Arch Biopartners Forms New Subsidiary to Pursue a Phase I Trial in Australia for Metablok (LSALT Peptide)

Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has formed a 100% owned subsidiary in Australia, named Arch Clinical Pty Ltd, to pursue an application to perform a phase I safety trial in...

Oct 29, 2018 09:00 am ET

Arch Biopartners Provides Toxicology Update for Metablok

Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF) today provided an update on the general results from toxicology and pharmacology studies evaluating Metablok, the Company’s lead drug candidate for treating acute...

Sep 26, 2018 09:29 am ET

Arch Biopartners Announces Completion of GMP Manufacturing of Metablok Vials

TORONTO, Sept. 26, 2018 /CNW/ - Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH) (OTCQB: ACHFF) today announced that Dalton Pharma Services (Dalton) has completed the good manufacturing practice (GMP) glass vial filling stage for Metablok, the Company's lead drug candidate for preventing acute kidney injury.

Aug 14, 2018 09:23 am ET

Arch Biopartners Engages Dalton Pharma Services for GMP Manufacturing of Metablok

TORONTO, Aug. 14, 2018 /CNW/ - Arch Biopartners, Inc., (Arch or the Company) (TSXV: ARCH) (OTCQB: ACHFF) a portfolio-based biotechnology company, today announced it has engaged Dalton Pharma Services (Dalton) to perform the good manufacturing practice (GMP) campaign for Metablok, (LSALT peptide), the Company's drug candidate for preventing acute kidney injury.

Jun 26, 2018 09:03 am ET

Arch Biopartners Receives $332,750 From the Exercise of Warrants

Arch Biopartners, Inc., (Arch or the Company) (TSX-V:ARCH) (OTCQB:ACHFF) a portfolio-based biotechnology company, today announced that it received net proceeds of $332,750 during the current quarter from the exercise of 665,500 warrants with an...

Jun 19, 2018 08:00 am ET

Arch Biopartners to Seek Regulatory Guidance From the U.S FDA for AB569

Arch Biopartners, Inc., (Arch or the Company) (TSX-V:ARCH) (OTCBB:ACHFF) a portfolio-based biotechnology company, today announced that it will seek regulatory guidance from the U.S. Food and Drug Administration (FDA) in a pre-Investigational New...

May 22, 2018 09:11 am ET

Arch Biopartners Engages Nucro-Technics To Complete Toxicology Studies To Support Investigational New Drug Application For Metablok

Arch Biopartners, Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCQB:ACHFF) a portfolio-based biotechnology company, today announced it has engaged Nucro-Technics in Scarborough, Ontario to complete the preclinical toxicology and pharmacology...

May 16, 2018 06:00 am ET

Arch Biopartners Announces Listing on OTCQB Exchange

Arch Biopartners, Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCQB:ACHFF) a portfolio-based biotechnology company, announced that the Company’s common shares have been approved to begin trading today on the OTCQB Venture Market (OTCQB) under...

May 08, 2018 09:25 am ET

Arch Biopartners Completes Pre-IND Meeting with U.S. FDA on LSALT Peptide for Preventing Acute Kidney Injury in Cardiac Surgery Patients

Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF), announced today it completed a successful pre-IND (Investigational New Drug) meeting via teleconference on April 18 with members of U.S. Food and Drug Administration...

Mar 27, 2018 09:08 am ET

Arch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569, Designed to Target Chronic Infection and Antibiotic Resistance

TORONTO, March 27, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF), announced today that the U.S. Patent and Trademark Office has issued U.S. Patent 9,925,206 protecting the composition and methods of use...

Mar 21, 2018 08:00 am ET

Arch Biopartners Granted Pre-Ind Meeting With FDA for Candidate Drug to Prevent Acute Kidney Injury

TORONTO, March 21, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF), announced today that a Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) Division of Cardiovascular and...

Mar 09, 2018 08:00 am ET

Arch Biopartners Closes $1.25M Non-Brokered Private Placement Financing

TORONTO, March 09, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) and (OTCBB:ACHFF), announced today it has closed the non-brokered private placement the Company disclosed in a press release January 26, 2018 (The...

Feb 27, 2018 07:30 am ET

Arch Biopartners Announces Start of GMP Manufacturing for Metablok at CSBio

TORONTO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX-V:ARCH) (OTCBB:ACHFF) a portfolio-based biotechnology company, today announced CSBio of Menlo Park, California, has started the good manufacturing practice (GMP) production campaign for Metablok,...

Feb 16, 2018 09:00 am ET

Arch Biopartners Closes Convertible Note Financing

TORONTO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX-V:ARCH) (OTCBB:ACHFF) announced it has closed the non-brokered, unsecured convertible note (“Note”) financing it announced in a press release February 8, 2018 for gross...

Feb 13, 2018 08:00 am ET

Arch Biopartners Announces AB569 Phase I Human Trial Begins Patient Recruitment and Enrollment Stage

TORONTO, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF) a portfolio based biotechnology company, announced today the investigator initiated phase I human trial for AB569 at the Cincinnati Veterans Affairs...

Feb 08, 2018 07:30 am ET

Arch Biopartners Arranges Convertible Note Financing

TORONTO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture:ARCH) (OTCBB:ACHFF), announced it has arranged a non-brokered, unsecured convertible note (“Note”) financing for gross proceeds of CAD $600,000 (the “Offering”).

Jan 26, 2018 08:50 am ET

Arch Biopartners Announces Non Brokered Private Placement Financing

TORONTO, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX-V:ARCH) (OTCBB:ACHFF) a portfolio based biotechnology company, intends to complete a non-brokered private placement offering of up to 2,500,000 common shares priced at $0.50...

Dec 06, 2017 10:08 am ET

Arch Biopartners Announces Completion of GMP Manufacturing of AB569 and Start Date of Phase I Trial

TORONTO, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF) today announced that the good manufacturing practice (GMP) production campaign for AB569 has been completed by Dalton Pharma Services. AB569 is...

Nov 01, 2017 10:09 am ET

Arch Biopartners Engages Nucro Technics to Begin Toxicology Studies for Metablok

TORONTO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX Venture:ARCH)(OTCBB:ACHFF) a portfolio-based biotechnology company, today announced it has engaged Nucro Technics in Scarborough, Ontario to perform preclinical toxicology and pharmacology studies for...

Oct 24, 2017 08:00 am ET

Arch Biopartners Closes Convertible Note Financing

Arch Biopartners Inc., ("Arch" or the "Company") (TSX VENTURE: ARCH)(OTCBB: ACHFF), announced it has closed a non-brokered, unsecured convertible note (the "Note") financing for gross proceeds of CAD $500,000 (the "Offering") on October 23, 2017.

Oct 24, 2017 07:58 am ET

Arch Biopartners Closes Convertible Note Financing

Arch Biopartners Inc., ("Arch" or the "Company") (TSX VENTURE:ARCH)(OTCBB:ACHFF), announced it has closed a non-brokered, unsecured convertible note (the "Note") financing for gross proceeds of CAD $500,000 (the "Offering") on October 23, 2017....

Oct 10, 2017 06:30 am ET

Arch Biopartners Initiates Manufacturing Process for Metablok

Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE: ARCH)(OTCBB: ACHFF) a portfolio-based biotechnology company, today announced it has engaged CSBio in Menlo Park, California, to begin the manufacturing process for Metablok, the Company's drug candidate for treating inflammation, cancer metastasis and sepsis.

Sep 28, 2017 08:30 am ET

Arch Biopartners' GMP Manufacturing of AB569 Progresses to Final Production Stage

Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE: ARCH)(OTCBB: ACHFF) today announced that the good manufacturing practice (GMP) production campaign for AB569 has advanced to the GMP glass vial filling stage. AB569 is the Company's inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) patients as well as many other indications.

Sep 28, 2017 08:28 am ET

Arch Biopartners' GMP Manufacturing of AB569 Progresses to Final Production Stage

Sep 12, 2017 08:59 am ET

Arch Biopartners Increases Non-Brokered Private Placement Financing

Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF), announced today it has increased the size of the non-brokered private placement the Company previously announced in a press release August 10, 2017, from $155,000 to...

Sep 12, 2017 08:59 am ET

Arch Biopartners Increases Non-Brokered Private Placement Financing

Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE: ARCH)(OTCBB: ACHFF), announced today it has increased the size of the non-brokered private placement the Company previously announced in a press release August 10, 2017, from $155,000 to $200,000 (the "Offering").

Aug 10, 2017 10:07 am ET

Arch Biopartners Closes Non-Brokered Private Placement Financing

Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE: ARCH)(OTCBB: ACHFF), announced today it has closed the non-brokered private placement the Company announced in a press release July 24, 2017 (The "Offering"). Pursuant to the Offering, Arch issued 310,000 Units priced at $0.50 per Unit (the "Units") for gross proceeds of $155,000. Each Unit consists of one common share of the Company and one common share purchase warrant (the "Warrant"). Each Warrant entitles the holder thereof to acquire one common share of the Company at an exercise price of $0.50 per

Aug 10, 2017 10:07 am ET

Arch Biopartners Closes Non-Brokered Private Placement Financing

Jul 27, 2017 12:43 pm ET

Arch Biopartners Provides Update on GMP Manufacturing of AB569

Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE: ARCH)(OTCBB: ACHFF) today provided an update on the progress of the good manufacturing practice (GMP) production campaign for AB569, the Company's inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) patients.

Jul 27, 2017 12:43 pm ET

Arch Biopartners Provides Update on GMP Manufacturing of AB569

Jul 24, 2017 04:00 pm ET

Arch Biopartners Retains Market Maker and Arranges Non Brokered Private Placement Financing

Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE: ARCH)(OTCBB: ACHFF) announced today it has retained Mackie Research Capital Corporation ("Mackie Research") to provide market-making services to the Company in compliance with, and subject to, the policies, guidelines and approval of the TSX Venture Exchange and other applicable legislation.

Jul 24, 2017 03:58 pm ET

Arch Biopartners Retains Market Maker and Arranges Non Brokered Private Placement Financing

Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) announced today it has retained Mackie Research Capital Corporation ("Mackie Research") to provide market-making services to the Company in compliance with, and subject to,...

May 04, 2017 01:35 pm ET

Arch Biopartners Announces Start of GMP Manufacturing for AB569 at Dalton Pharma Services

Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ARCH)(OTCBB:ACHFF) a portfolio-based biotechnology company, today announced Dalton Pharma Services (Dalton) has launched the good manufacturing practice (GMP) campaign for AB569, the...

May 04, 2017 01:35 pm ET

Arch Biopartners Announces Start of GMP Manufacturing for AB569 at Dalton Pharma Services

Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE: ARCH)(OTCBB: ACHFF) a portfolio-based biotechnology company, today announced Dalton Pharma Services (Dalton) has launched the good manufacturing practice (GMP) campaign for AB569, the Company's inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs.

Apr 18, 2017 09:17 am ET

Grant of Options to Directors, Officers and Scientists

Apr 18, 2017 09:17 am ET

Grant of Options to Directors, Officers and Scientists

Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE: ARCH)(OTCBB: ACHFF) announces the Company's board has granted a total of 2,100,000 stock options to its directors, officers and certain scientists pursuant to the Company's stock option plan and the requirements of the TSX Venture Exchange (TSXV). The grant of options to the directors and the scientists represent their remuneration during the current year for serving on the board or working on Arch drug development respectively. The grant of options to the officers is for the year ended September 30, 2016.

Apr 13, 2017 08:37 am ET

Arch Biopartners' Lead Anti-Bacterial Drug Candidate AB569 to Enter Investigator-Sponsored Phase I Human Trial

Apr 13, 2017 08:37 am ET

Arch Biopartners' Lead Anti-Bacterial Drug Candidate AB569 to Enter Investigator-Sponsored Phase I Human Trial

Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE: ARCH)(OTCBB: ACHFF) a portfolio-based biotechnology company, today announced that the Cincinnati Veterans Affairs Medical Center (CVAMC) will conduct an investigator initiated Phase I human trial to evaluate the safety and pharmacokinetic profile of AB569, the Company's inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs.

Feb 28, 2017 09:18 am ET

Arch Biopartners Closes Non-Brokered Private Placement Financing

Feb 28, 2017 09:18 am ET

Arch Biopartners Closes Non-Brokered Private Placement Financing

Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE: ARCH)(OTCBB: FOIFF) a portfolio based biotechnology company, announced today it has raised $400,000 with the closing of the non-brokered private placement the Company announced in a press release February 21, 2017 (The "Offering"). Pursuant to the Offering, Arch issued 1,000,000 common shares priced at $0.40 per common share (the "Common Shares"). All Common Shares issued in connection with the Offering will be subject to a hold period of four months and one day from the closing date.

Ad blocking detected

Arch Biopartners Inc. (V:ARCH)

Business Focus: Biotechnology & Medical Research (NEC)